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Summary
The major histocompatibility complex class I mole-
cules display peptides (pMHC I) on the cell surface
for immune surveillance by CD8+ T cells. These pep-
tides are generated by proteolysis of intracellular poly-
peptides by the proteasome in the cytoplasm and then
in theendoplasmic reticulum (ER)by theERaminopep-
tidase associated with antigen processing (ERAAP).
To define the unknownmechanism of ERAAP function
in vivo, we analyzed naturally processed peptides in
cells with or without appropriate MHC I and ERAAP.
In theabsenceofMHC I,ERAAPdegraded theantigenic
precursors in the ER. However, MHC Imolecules could
bind proteolytic intermediates and were essential for
generation of the final peptide by ERAAP. Thus,
ERAAP synergizes with MHC I to generate the final
pMHC I repertoire.
Introduction
The display of peptides representing endogenous pro-
teins by the major histocompatibility complex class I
molecules (MHC I) is essential for immune surveillance
(Shastri et al., 2002; Yewdell et al., 2003; Trombetta
and Mellman, 2005). Normally, the peptides are derived
from self-proteins, but if the cells are infected with vi-
ruses or bacteria or harbor mutated genes, novel nonself
peptides from these sources are also generated. The
presence of these foreign peptides in the mix displayed
by the MHC class I molecules allows CD8+ T cells to de-
tect intracellular abnormalities and to cause the elimina-
tion of these cells. Effective immune surveillance by the
CD8+ T cell repertoire therefore depends upon the anti-
gen-processing pathway to efficiently generate the
peptide-MHC I (pMHC I) repertoire.
MHC I molecules are highly polymorphic in every spe-
cies examined (Klein and Figueroa, 1986). Since the
early 1990s it has been known that each MHC I molecule
displays a set of peptides that number in the thousands
but share a distinct consensus motif defined by length
and two or three conserved amino acids. For example,
the Kb MHC I displays 8mer peptides with the consensus
motif XXXX[Y,F]XX[L,M,V,I] (where X = any amino acid),
and the Ld MHC I displays a different set of 9mer pep-
tides with the consensus motif X[P,S]XXXXXX[F,L,M]
(Falk et al., 1991; Corr et al., 1992; Rammensee et al.,
1997). Yet all the known components of the MHC pro-
*Correspondence: nshastri@berkeley.educessing pathway are essentially conserved within and
across species (Paulsson, 2004). This raises the intrigu-
ing question of how the same antigen-processing
machinery can efficiently generate the diverse sets of
precisely cut peptides that conform to the distinct con-
sensus motifs of all the different MHC I molecules.
The MHC I antigen-processing pathway begins in the
cytoplasm (Townsend et al., 1986). Many antigenic pre-
cursors enter the pathway when they are synthesized as
defective or cryptic ribosomal products or when they are
retrieved from other subcellular compartments into the
cytoplasm (Shastri et al., 2002; Yewdell et al., 2003;
Trombetta and Mellman, 2005). The notion that the final
antigenic peptides are generated in the cytoplasm itself
prior to their transport into the ER appears to have lost
its initial appeal (Saveanu et al., 2002; Shastri et al.,
2002; Rock et al., 2004; Trombetta and Mellman, 2005).
For most antigenic precursors, it is now believed that
proteolysis in the cytoplasm generates the C terminus
of the final antigenic peptide, but its N terminus is gener-
ated only after its transport by the transporter associ-
ated with antigen processing (TAP) in the ER compart-
ment (Cascio et al., 2001; Kunisawa and Shastri, 2003).
The ER enzyme that trims the N-terminally extended
peptide precursors to their final length has also been
identified as the ER aminopeptidase associated with an-
tigen processing (ERAAP) in mice (Serwold et al., 2002)
and as ER aminopeptidase 1 (ERAP1) in humans (Saric
et al., 2002). Indeed, inhibition of ERAAP expression
with RNA interference or by homologous recombination
disrupts the pMHC I repertoire (Serwold et al., 2002;
York et al., 2002; Hammer et al., 2006; Yan et al., 2006).
In the absence of ERAAP, some peptides remained un-
changed while others were either dramatically up- or
downregulated. There are thus compelling reasons to
believe that trimming N termini from antigenic precur-
sors in the ER is a key step in generating the normal
pMHC I repertoire on the cell surface.
The molecular mechanism for ERAAP function, how-
ever, remains obscure. Based upon ERAAP’s ability to
trim peptides in vitro, it has been argued that ERAAP
alone or in concert with another related aminopeptidase,
leukocyte-derived arginine aminopeptidase (L-RAP), is
sufficient to generate the final peptide (York et al.,
2002; Saveanu et al., 2005). In another study that used
a panel of synthetic peptides and recombinant ERAP1,
it was found that ERAP1 exhibits substrate preferences
defined by peptide length and the C-terminal residue
(Chang et al., 2005). Thus, it has been proposed that
ERAP1 acts as a unique ‘‘molecular ruler’’ to generate
the correct 8–10 amino acid peptides that can then
bind the available MHC I molecules. On the other
hand, analysis of ERAAP-deficient mice also revealed
substrate preferences for ERAAP (Hammer et al., 2006;
Yan et al., 2006) but did not support the molecular ruler
mechanism. In vivo, ERAAP generated octa- and nona-
peptides presented by different MHC I, yet inexplicably
degraded other similarly sized peptides. These discrep-
ancies make it difficult to extrapolate the results of
in vitro studies to the normal function of ERAAP in the
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ysis did not include MHC I molecules, it is not known
whether ERAAP activity is influenced by MHC I. Thus,
the intriguing question of whether MHC I serve an active
or a passive role in the generation of the final pMHC I
repertoire has remained an enduring mystery for more
than 15 years (Elliott et al., 1990; Falk et al., 1990).
Here we use cells derived from ERAAP-deficient mice
to analyze the N-terminal trimming of peptides by
ERAAP in the presence or absence of relevant MHC I
molecules. We find that MHC molecules play a key role
in determining whether ERAAP’s enzymatic activity
eliminates antigenic precursors or generates the final
pMHC I complex. Thus, ERAAP and MHC I synergize
to generate the customized peptide repertoires appro-
priate for each of the polymorphic MHC I molecules.
Results
ERAAP Generates pMHC I from N-Terminally
Extended Precursors in the ER
First we established the model system for studying
ERAAP function in the MHC class I processing pathway.
The antigenic precursors were targeted directly into the
ER by appending their coding sequence downstream of
an ER translocation signal (ES). The DNA constructs
were then transfected into a fibroblast cell line derived
from C57BL/6 (H-2b) mice lacking either the transporter
associated with antigen processing alone (TAP-defi-
cient) or both ERAAP and TAP (ERAAP-TAP double-
deficient) described earlier (Hammer et al., 2006). This
strategy allows antigen processing to be confined to
the ER itself, because the products generated by normal
cytoplasmic proteolysis cannot enter the ER in the ab-
sence of TAP. Expression of the pMHC I on the cell sur-
face was measured by coculturing the transfected cells
with appropriate lacZ-inducible T cell hybridomas. The
SHL8-Kb complex (peptide SHL8 = SIINFEHL in single
amino acid code) recognized by the B3Z T cell hybrid-
oma was efficiently generated in TAP-deficient cells
when they were transfected with the ER-targeting con-
structs. The ES-X5[SHL8] precursor, containing five N-
terminal flanking residues (AIVMK), or the ES-[SHL8]
precursor without any N-terminal flanking residues
yielded comparable responses (Figure 1A, left). The
ES-[SHL8] precursor yields the final SHL8 peptide after
the ES sequence is cleaved off by the signal peptidase
in the ER and thus does not require any further trimming.
In contrast, the ES-X5[SHL8] construct yields the
X5[SHL8] peptide after the ES sequence is removed
and thus requires that the five N-terminal flanking resi-
dues be trimmed to generate the final SHL8 peptide.
The comparable activity of the trimming-dependent
ES-X5[SHL8] and the trimming-independent ES-[SHL8]
precursors shows that trimming occurred efficiently in
the presence of ERAAP in the ER of TAP-deficient cells.
When fibroblasts lacking both ERAAP and TAP were
transfected with the same constructs, cells expressing
the trimming-dependent ES-X5[SHL8] precursor were
deficient in their ability to generate the B3Z stimulating
SHL8-Kb complex (Figure 1A, right). However, the
same cells expressing the trimming-independent ES-
[SHL8] precursor did generate the SHL8-Kb complex,
demonstrating that the absence of ERAAP did not affectother aspects of MHC loading and transport to the cell
surface.
To directly establish that ERAAP expression was re-
quired for generating the final peptide from its N-termi-
nally extended precursors, we cotransfected antigenic
constructs into ERAAP-TAP double-deficient cells to-
gether with either vector alone or the cDNA encoding
mouse ERAAP. Reconstitution of ERAAP expression in
the ERAAP-TAP double-deficient cells dramatically en-
hanced the presentation of the B3Z-stimulating SHL8-
Kb complex from the ES-X5[SHL8] construct. Likewise,
the presentation of the final pMHC I (SVL9-Db, WI9-Db,
and QL9-Ld) from three other N-terminally extended pre-
cursors was also markedly improved in the presence of
ERAAP (Figure 1B). Thus, ERAAP was required for trim-
ming the N-terminal flanking residues from the final pep-
tides presented by Kb, Db, or Ld MHC I molecules. The
source of the low T cell-stimulating activity of trans-
fected cells in the absence of ERAAP is presently un-
clear. It is possible that a small amount of the final pep-
tide might have been generated because of occasional
inaccuracy with which the signal peptidase cleaved
the ES sequence. Alternatively, an ERAAP-independent
pathway might have generated the final peptides. Re-
gardless of the reason for the background activity, the
presence of ERAAP reproducibly and markedly en-
hanced the presentation of all the ER-targeted precur-
sors tested here.
Generation of the Final pMHC I Requires ERAAP
Localization in the ER
To determine whether the trimming of antigenic precur-
sors required ERAAP activity in the ER compartment it-
self, we tested mutant ERAAP molecules that could not
enter the ER or were functionally inactive (Figure 2A). We
first deleted the predicted N-terminal ER translocation
signal of ERAAP by generating a cDNA construct lacking
nucleotides encoding residues 2–20 (ERAAPDES). Un-
like expression of wild-type ERAAP (ERAAP WT), which
clearly allowed the efficient presentation of the N-termi-
nally extended ES-X9[SHL8] precursor in ERAAP-TAP
double-deficient cells, the presentation activity of cells
expressing the ERAAPDES was comparable to those ex-
pressing vector alone (Figure 2B). To confirm that the
deletion of the ERAAP signal sequence did result in its
exclusion from the ER, we used immunofluorescent la-
beling to detect ERAAP. The ERAAP polyclonal anti-
bodies readily reacted with ERAAP in transfected cells
but did not crossreact with the endogenous monkey
ERAAP presumably present in vector-transfected cells
(Figure 2C). Furthermore, the punctate staining pattern
in ERAAP WT transfected cells suggested that it was lo-
calized in the ER. The ER location of ERAAP was further
established when ERAAP was found to colocalize with
other ER-resident proteins containing the KDEL motif
detected with the KDEL antibody (Figure 2D). In con-
trast, cells expressing the ERAAPDES mutant showed
a distinct staining pattern consistent with its localization
to the cytoplasm and it clearly did not colocalize with the
ER proteins containing the KDEL motif (Figure 2D). To
further biochemically confirm these differences in intra-
cellular locations, we tested the sensitivity of ERAAP WT
and ERAAPDES to endoglycosidase H (Endo H). Immu-
noblot analysis of Endo H-treated lysates showed
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797Figure 1. ERAAP Is Essential for Generating pMHC I on the Cell Surface from ER-Targeted N-Terminally Extended Precursors
(A) The DNA constructs encoding the vector alone or the SHL8 (SIINFEHL) antigenic peptide downstream of an ER-targeting signal sequence (ES)
were transiently transfected into fibroblasts derived from either TAP-deficient or ERAAP-TAP double-deficient mice. The constructs included
either no (ES-[SHL8]) or five (ES-X5[SHL8], X5 = AIVMK) additional amino acids between the signal peptidase cleavage site of the ES-signal se-
quence and the SHL8 peptide. 2 days later, indicated number of transfected cells were incubated overnight with the lacZ-inducible, SHL8-Kb-
specific B3Z T cell hybridoma. The lacZ activity was measured by the conversion of the substrate chlorophenolred-b-D-galacto-pyrannoside into
chlorophenol red, which absorbs light at 595 nm.
(B) ER-targeted, N-terminally extended versions of the antigenic peptides SHL8, SVL9 (SSVVGVWYL), WI9 (WMHHNMDLI), or QL9 (QLSPFPFDL)
were cotransfected with either vector alone or mouse ERAAP into ERAAP-TAP double-deficient fibroblasts. The cDNA encoding Ld was also
included with the ES-X6[QL9] construct. 2 days later, varying number of transfected cells were used as APCs for the indicated T cells, and their
lacZ response was measured as in (A). The MHC molecule presenting the peptides is shown in parentheses. Data are representative of at least
three independent experiments.a decrease in the molecular weight of ERAAP WT pro-
tein, reflecting glycosylation consistent with ER localiza-
tion (Figure 2E). In contrast, the lysate of ERAAPDES-
transfected cells contained ERAAP of a lower molecular
weight than ERAAP WT and was not decreased by treat-
ment with Endo H, indicating cytoplasmic localization
where N-linked glycosylation does not occur (Figure 2A).
Although these results do not address what role, if any,
ERAAP could play in the cytoplasm, they provide direct
evidence that the putative ES signal is functional. It al-
lows ERAAP’s entry into the ER wherein ERAAP is glyco-sylated and generates the final SHL8 peptide from its
N-terminally extended precursor.
Generation of the Final pMHCI Requires
ERAAP Activity
Next we assessed whether the enzymatic activity of
ERAAP was required to generate the final peptide. Pre-
vious studies had identified two key sequence motifs
in aminopeptidases similar to ERAAP (Figure 2A): the
GAMEN (aa 306–310 in mouse and aa 317–321 in human)
and the HExxHx18E motifs that are involved in binding
Immunity
798Figure 2. The Generation of pMHC I from N-Terminally Extended Precursors Requires ERAAP Expression in the ER Compartment
(A) Schematic of mouse ERAAP containing the putative ER translocation signal (ES), the aminopeptidase core, and potential N-linked glycosyl-
ation sites. The sequence alignment of the aminopeptidase core with the human and rat orthologs is shown with the conserved GAMEN and zinc
binding motifs (boxed).
(B) Deletion of the ES sequence eliminates ERAAP function. The wild-type ERAAP (ERAAP WT), its ES deletion mutant (ERAAPDES), or vector
alone were cotransfected with the ER-targeted antigenic precursor ES-X9[SHL8]. Surface expression of SHL8-Kb complex was measured with
B3Z T cells.
(C) Polyclonal rabbit anti-mouse ERAAP antibodies specifically stain ERAAP-transfected COS cells. The COS cells were transfected with either
vector or ERAAP cDNA and stained with the primary and secondary antibodies 2 days later as described in the Experimental Procedures.
(D) Deletion of ES signal alters the intracellular location of ERAAP from the ER to the cytoplasm. COS cells transfected with either ERAAP WT or
ERAAPDES were stained with the ERAAP (green) or the ER marker KDEL (red) antibody. The merged image shows an overlay of green and red
stains as yellow.
(E) ERAAP without the ES signal remains unglycosylated. The extracts of COS cells transfected with ERAAP WT or ERAAPDES were either un-
treated or treated with Endo H. The samples were separated by SDS-PAGE, transferred to the nitrocellulose membranes, and immunoblotted
with the ERAAP antibody. Data are representative of at least two independent experiments.the substrate and the metal atoms that serve as cofac-
tors for enzymatic activity. We substituted the nucleo-
tides GAA for GCC in human ERAAP, thus changing
the glutamic acid (E) at residue 320 to an alanine (A).
To test its function, the E320A ERAAP mutant was
cotransfected with the ES-X5[SHL8] precursor into
ERAAP-TAP double-deficient cells (Figure 3A). Like
its mouse counterpart, the wild-type human ERAAP
(hERAAP WT) was fully capable of restoring the impaired
antigen presentation function of transfected cells, but
the activity of the E320A mutant was similar to that of
vector alone. Both the hERAAP WT and the E320A mu-
tants were expressed at similar amounts as judged by
immunoblot analysis of total cell lysates (Figure 3B).
The results show that ERAAP function was dependent
upon the presence of an intact GAMEN motif and thus
on its enzymatic activity.
To directly assess the fate of the antigenic precur-
sors in the presence or absence of ERAAP in the trans-
fected cells, we analyzed cell extracts by HPLC frac-tionation (Figure 3C). To allow the detection of N-
terminally extended precursors, each fraction was
treated with trypsin, which cleaves the carboxyl termi-
nus of the lysine (K) residue flanking the N terminus of
the SHL8 peptide. This allows the release of the opti-
mally active SHL8 octapeptide from its precursors
and allows their detection despite their poor antigenic-
ity in the in vitro peptide assay (Paz et al., 1999). In
ERAAP-TAP double-deficient cells transfected with
the ES-X5[SHL8] precursor and vector alone, a single
peak of activity was detected in fraction 63 represent-
ing the ER precursor of SHL8 peptide. By contrast, in
cells cotransfected with the hERAAP WT, this late elut-
ing activity was not detected and instead two new pep-
tide peaks were found that coeluted with the Kb and Db
binding SHL8 octapeptide and K[SHL8] nonapeptide,
respectively (Malarkannan et al., 1995). Notably, the
HPLC profile of extracts from cells cotransfected with
the E320A mutant was identical to that of cells trans-
fected with vector alone. This analysis directly
MHC I-Dependent Peptide Trimming by ERAAP
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(A) The cDNAs encoding either vector alone, human ERAAP WT, or its single amino acid mutant in the GAMEN motif (E320A) were cotransfected
into ERAAP-TAP double-deficient fibroblasts together with the ES-X5[SHL8] construct. After 2 days, expression of SHL8-Kb complex was
measured with B3Z T cells.
(B) The hERAAP WT and its E320A mutant are expressed at comparable amounts. The amounts of hERAAP WT, its E320A mutant, or vector alone
as a negative control were determined by immunoblotting transfected COS cell lysates with the hERAAP antibody.
(C) The conversion of the N-terminally extended precursor to the final SHL8 or K[SHL8] peptides presented by Kb or Db MHC occurs only in the
presence of hERAAP WT. The peptide extracts from ERAAP-TAP double-deficient fibroblasts transfected with ES-X5[SHL8] and either vector
alone, hERAAP WT, or its E320A mutant were fractionated by RP-HPLC. The SHL8-containing, N-terminally extended intermediates were de-
tected after trypsin treatment of each fraction and incubating them with B3Z T cells in the presence of the appropriate APC. The peaks were
identified, where known, by comparison with synthetic peptides run under identical conditions. Data are representative of at least two indepen-
dent experiments.demonstrates (1) that it is possible to detect precursor
peptides in the ER, (2) that human ERAAP is function-
ally equivalent to mouse ERAAP, and (3) that ERAAP’s
enzymatic activity is necessary for generating the final
MHC-bound peptides from the N-terminally extended
precursor.
ERAAP Degrades ER Peptides but Generates the
Final Peptide in the Presence of Appropriate MHC I
To define the potential relationship between the MHC
molecules and ERAAP function, we used the QL9-Ld-
specific T cell hybridoma 2CZ because the ERAAP-
TAP double-deficient cells, derived from the B6 (H2b)
background, do not express the Ld MHC molecule.
This makes it possible to analyze the fate of antigenic
precursors in the presence or absence of ERAAP and
Ld MHC. The ERAAP-TAP double-deficient cells gener-
ated the QL9-Ld complex from the ES-X6[QL9] precur-
sor only when they were cotransfected with ERAAP
and the Ld MHC (Figure 4A). In the absence of ERAAPor in its presence with the irrelevant Kd MHC molecule,
the cells were unable to serve as APCs for the 2CZ T
cells. Thus, both ERAAP and Ld MHC were essential
for generating the QL9-Ld complex from its ER-targeted
ES-X6[QL9] precursor.
To determine whether ERAAP trimmed peptides in
the ER in the presence or absence of the cognate Ld
MHC, we analyzed naturally processed peptides ex-
tracted from cells expressing the ES-IVMQLK[QL9]
(ES-X6[QL9]) precursor. This precursor, similar to
the ES-X5[SHL8] precursor (Figure 3), also contains a
N-terminal flanking lysine residue that allows the release
of optimally active QL9 peptide after trypsin treatment
of the HPLC fractions. In acid pH, the N-terminal gluta-
mine (Q) residue cyclizes to a pyroglutaminyl residue
and thus migrates slower than the native QL9 peptide
(Figure 4B; Kageyama et al., 2001). The cyclized QL9
is nevertheless a potent stimulator of 2CZ T cells and
can be clearly distinguished from its 15mer X6[QL9]
precursor after HPLC fractionation.
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(A) Generation of the QL9-Ld complex in ERAAP-TAP double-deficient fibroblasts from the ER-targeted ES-X6[QL9] precursor requires ERAAP
and the Ld MHC. The ERAAP-TAP double-deficient fibroblasts were cotransfected with the ES-X6[QL9] precursor and other cDNAs shown.
Expression of the QL9-Ld complex was detected with lacZ-inducible 2CZ T cell hybridoma as in Figure 1.
(B) Synthetic IVMQLK[QL9] and the QL9 peptides can be resolved by HPLC and detected by 2CZ T cells. 10 fmoles of indicated peptides were
injected into the HPLC. Each fraction was treated with trypsin and assayed with 2CZ T cells and Ld-L cells as APCs.
(C) ERAAP generates the final QL9 peptide from the X6[QL9] precursor in the presence of Ld but degrades the precursor peptide in the absence of
Ld. The ERAAP-TAP double-deficient fibroblasts were cotransfected with the ES-X6[QL9] precursor construct and either vector alone, ERAAP
alone, or ERAAP plus Ld. The peptides were extracted from the transfected cells and fractionated by HPLC. Each fraction was treated with tryp-
sin and used to stimulate 2CZ T cells in the presence of Ld-L cells as APCs.
(D) The absence of ERAAP cannot be compensated by other proteases. The ERAAP-TAP double-deficient fibroblasts were transfected with the
ES-X6[QL9] construct with either vector alone or Ld, and cell extracts were analyzed for 2CZ activation after HPLC fractionation and trypsin treat-
ment of each fraction.
(E) Generation of the final QL9 peptide from its X6[QL9] precursor in the presence of Ld requires enzymatically active ERAAP. The ERAAP-TAP
double-deficient fibroblasts were cotransfected with the ES-X6[QL9] precursor, Ld, and either hERAAP WT or its enzymatically inactive mutant
E320A. The cell extracts were analyzed for 2CZ activation after HPLC fractionation and trypsin treatment. Data are representative of at least three
(C) or two independent experiments.In trypsin-treated HPLC fractions of the extract from
vector and ES-X6[QL9]-transfected ERAAP-TAP dou-
ble-deficient cells, we found a single peak of antigenic
activity that coeluted with the X6[QL9] peptide (Fig-
ure 4C, top). Clearly, the cells generated the X6[QL9] an-
tigenic precursor and it was readily detected in the cell
extracts. Remarkably, when the same cells were co-
transfected with the ES-X6[QL9] construct and ERAAP,
the amount of X6[QL9] precursor was dramatically re-
duced (Figure 4C, middle). Notably, the loss of X6[QL9]
precursor was not accompanied by comparable amount
of its QL9 product (Figure 4C, middle versus top). To de-
termine whether the trimming activity of ERAAP could
be influenced by MHC I, we analyzed extracts of cells
cotransfected with the antigenic construct ERAAP and
the Ld MHC. In contrast to cells expressing ERAAP with-
out Ld, approximately 6-fold higher amount of QL9 pep-tide was now found in cells expressing ERAAP and Ld
(Figure 4C, bottom). Thus, ERAAP was capable of trim-
ming the X6[QL9] precursor, but instead of efficiently
converting it to the final QL9 peptide, the precursor
was degraded to a length that was no longer recognized
by the 2CZ T cells. However, in the presence of the
ERAAP and the appropriate Ld, the QL9 peptide was ef-
ficiently generated from its X6[QL9] precursor. We con-
clude that the appropriate MHC I protected the antigenic
precursor from degradation by ERAAP and facilitated
the generation of the final peptide.
To determine whether ERAAP was uniquely required
to generate QL9 from its X6[QL9] precursor, we also an-
alyzed extracts of cells transfected with the ES-X6[QL9]
construct with or without Ld (Figure 4D). In either case,
only the X6[QL9] precursor was detected in the cells, in-
dicating that Ld by itself was insufficient to generate the
MHC I-Dependent Peptide Trimming by ERAAP
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(A) Purified recombinant ERAAP (rERAAP) is active in trimming the model LpNA substrate, and leucinethiol inhibits this activity. The rERAAP
purified from baculovirus-infected insect cells was incubated with Leucine pnitroanilide (LpNA) with or without leucinethiol (LeuSH) and DTT,
which is required to keep LeuSH in its reduced and active form. The LpNA hydrolysis was measured as light absorbance at 415 nm.
(B) The indicated synthetic peptides were incubated with either buffer alone or with rERAAP. The peptides were assayed by their ability to stim-
ulate 2CZ T cells in the presence of Ld-L cells as APCs. To detect the generation of QL9 peptide from its N-terminally extended X6[QL9] precursor,
the peptides were either assayed as such or after trypsin treatment.
(C) The Ld MHC protects QL9 but not SHL8 peptide from degradation by rERAAP. Synthetic QL9 or SHL8 peptides were incubated with buffer or
rERAAP in the presence or absence of recombinant Ld-Ig fusion protein. The QL9 and SHL8 peptides were assayed with 2CZ or B3Z T cells and Ld
or Kb-L cells as APCs, respectively. The graph shows the mean values with SD from three independent experiments (A–C).QL9 peptide and that other proteases did not compen-
sate for the absence of ERAAP. Finally, we cotrans-
fected cells with the E320A active site mutant of ERAAP
with the antigenic construct and Ld (Figure 4E). Again,
the final QL9 peptide was predominant in extracts of
cells expressing Ld and wild-type ERAAP, but only the
X6[QL9] precursor was predominant in cells expressing
Ld and the inactive E320A mutant. We conclude that the
generation of the final QL9 peptide requires both the rel-
evant Ld MHC molecule as well as enzymatically active
ERAAP.
Recombinant ERAAP Degrades Synthetic Peptides
In Vitro
To establish that ERAAP could directly trim antigenic
precursor and the final peptides, we used recombinant
ERAAP (rERAAP) purified from baculovirus-infected in-
sect cells. Like the material purified from mouse micro-
somes in a previous study (Serwold et al., 2002), rERAAP
also efficiently cleaved its synthetic Leucine p nitroani-
lide (LpNA) substrate, and this activity was completely
inhibited by the aminopeptidase inhibitor leucinethiol
(Figure 5A). We incubated synthetic QL9 and X6[QL9]
peptides with rERAAP and analyzed the peptide prod-
ucts for their ability to stimulate the 2CZ T cells. After
90 min incubation at 37C, ERAAP trimmed the QL9 pep-tides into shorter products that were no longer recog-
nized by the 2CZ T hybridoma (Figure 5B). Likewise,
the X6[QL9] precursor peptide was also trimmed into
peptides shorter than QL9 because longer peptides, if
present, are detectable after trypsin treatment. Although
it is not possible to rule out undetectable contaminants,
in our hands both the precursor and final peptides were
ERAAP substrates and ERAAP trimmed them beyond
the nine QL9 residues.
Next we tested the influence of Ld MHC in this in vitro
peptide-trimming reaction. Inclusion of recombinant Ld
in the reaction mixture increased the recovery of anti-
genic QL9 peptide (Figure 5C). The ability of Ld to protect
the QL9 peptide was specific because inclusion of Ld did
not prevent the degradation of another final SHL8 pep-
tide by ERAAP. Likewise, recombinant Kb protected
only the SHL8 peptide (see Figure S1A in the Supple-
mental Data available online). In other time course ex-
periments, the inclusion of Ld did not, however, enhance
the rate at which QL9 was generated from its precursor,
suggesting that at least in vitro Ld does not bind and pro-
tect N-terminally extended peptides (Figure S1B). We
conclude that ERAAP can degrade the precursor as
well as the final peptide and that the presence of the ap-
propriate MHC I molecules slows the degradation of the
final peptide.
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(A) The presence of a proline residue among the N-terminal flanking residues inhibits ERAAP’s ability to generate the final QL9-Ld complex. The
ERAAP-TAP double-deficient fibroblasts or COS cells were cotransfected with ER-targeted, N-terminally extended QL9 precursors without (ES-
X6[QL9]) or with (ES-X3-EPK[QL9]), a proline residue (P), the Ld MHC, and either ERAAP or vector alone. The presence of the QL9-Ld complex on
the cell surface was measured with 2CZ T cells.
(B) The TAP inhibitor ICP47 blocks presentation of cytoplasmic but not ER-targeted QL9 precursors in COS cells. Simian COS cells were cotrans-
fected with constructs encoding cytoplasmic (MK[QL9]) or ER-targeted (ES-X6[QL9], ES-X3-EPK[QL9]) precursors, and the indicated cDNAs
encoding Ld, ICP47, or vector alone. The presence of the QL9-Ld complex on the cell surface was measured with 2CZ T cells. Data are repre-
sentative of at least two independent experiments. The similar results were confirmed by using either ES-X3-LPK[QL9] or -QPK[QL9] instead
of -EPK[QL9] (data not shown).Model for Detecting MHC I-Bound
Antigenic Precursors
The profound influence of the MHC I on the recovery of
the final peptide suggested that the N-terminally ex-
tended peptide precursors might be trimmed while
they were bound to the MHC I molecule. Indeed, in an
in vitro peptide-trimming model with purified micro-
somes, we had shown earlier that N-terminally extended
peptides could bind MHC I as potential intermediates for
the generation of the final pMHC I (Brouwenstijn et al.,
2001). However, other studies that have examined pep-
tide trimming in microsomes have either supported
a role for MHC I (Komlosh et al., 2001) or have argued
against it (Fruci et al., 2001). Nevertheless, whether
MHC I molecules interact with antigenic precursors in
living cells remains unknown. This is the case possibly
because such interactions, even if they occur, are likely
to be transient and would make the complexes too rare
to be detected in conventional assays.
To detect the putative complexes containing N-termi-
nally extended intermediates bound to MHC molecules
in living cells, we made several modifications to our
model system. First, we altered the antigenic precursor
to make its products resistant to ERAAP. We took ad-
vantage of the fact that peptides with the structure ‘‘X-
P-Xn’’ (P = proline and X = any amino acid) are ineffi-
ciently trimmed by ERAAP in the ER (Serwold et al.,
2001, 2002). A proline residue was inserted within theN-terminal residues flanking QL9 in its ER-targeted pre-
cursor ES-X3-EPK[QL9]. We reasoned that the presence
of the proline residue within the N-terminal flanking res-
idues would prevent ERAAP from trimming beyond the
penultimate glutamic acid (E) residue, resulting in the
12mer peptide EPK[QL9].
We transfected the QL9 precursor constructs in
ERAAP-TAP double-deficient cells. As before, cells ex-
pressing the ES-X6[QL9] construct as well as the Ld
MHC and ERAAP generated the 2CZ-stimulating QL9-
Ld complex on their surface (Figure 6A). In contrast,
the same cells failed to generate the QL9-Ld complex
from the ES-X3-EPK[QL9] precursor despite the pres-
ence of both Ld and ERAAP. Thus, the presence of the
proline residue effectively inhibited the cells’ ability to
generate the final QL9 peptide.
Second, to ensure high expression of the antigenic
precursor and the Ld MHC, we used monkey COS cells
as APCs. The COS cells express high amounts of endog-
enous MHC and can be efficiently transfected with
mouse MHC and antigenic precursors to serve as
APCs (Karttunen et al., 1992). Furthermore, as in human
cells, the monkey TAP in COS cells can be inhibited with
the TAP inhibitor ICP47 (Hill et al., 1995; Serwold et al.,
2001). Indeed, when cells were cotransfected with Ld
and the construct expressing MK[QL9], a cytoplasmic
QL9 precursor, the presentation of QL9-Ld complex
was strongly inhibited in the presence of ICP47
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(A) Trypsin treatment of N-terminally extended QL9 precursor EPK[QL9] enhances its antigenicity. Varying concentrations of synthetic QL9 and
its N-terminally extended analog EPK[QL9] peptide were tested for their ability to stimulate 2CZ T cells with Ld-L cells as APC. The peptides were
tested as such or after preincubation with trypsin.
(B) The final antigenic QL9 peptide, its N-terminally extended precursors and intermediates present in the total peptide extract of COS cells trans-
fected with ES-X3-EPK[QL9], Ld, and ICP47. The extract was fractionated by HPLC and antigenic peptides detected in the fractions by their abil-
ity to stimulate 2CZ response after trypsin treatment. HPLC fractions collected after injection of buffer alone were tested in parallel to rule out
carryover between samples.
(C) The Ld MHC was immunoprecipitated from detergent lysate of COS cells transfected with the ES-X3-EPK[QL9] construct, Ld, and ICP47
cDNAs. The peptides contained in the immunoprecipitated material were fractionated by HPLC and assayed with 2CZ T cells with (closed circle)
or without (open circle) trypsin treatment.
(D) As controls, the same cell lysate was immunoprecipitated with the pan HLA (W6/32) antibody (triangle), or the lysate from cells without Ld
transfection was immunoprecipitated with the Ld antibody (circle). The peptide content of the immunoprecipitated material was analyzed as
above. Data are representative of at least three independent experiments.(Figure 6B). In contrast, when COS cells were cotrans-
fected with the ER-targeted ES-X6[QL9] construct and
ICP47, the presentation of QL9-Ld complex was en-
hanced. The enhanced presentation is likely due to re-
duced competition from the pool of Ld binding precur-
sors that are normally transported by TAP. As noted
above, the presentation activity of the precursor with
a proline residue in the N-terminal flanking position
was lower than one without a proline residue. Thus, as
in TAP-deficient fibroblasts, expression of ICP47 in
COS cells allows processing of ER-targeted antigenic
precursors.N-Terminally Extended Proteolytic Intermediate
Is Bound by Ld MHC I
We cotransfected COS cells with the proline precursor
ES-X3-EPK[QL9] together with Ld and ICP47. Like the
other N-terminally extended peptides used above, the
ES-X3-EPK[QL9] peptide also contains a lysine (K) resi-
due flanking the final QL9 peptide. As seen by the dra-
matic increase in antigenicity of the synthetic EPK[QL9]
peptide after trypsin treatment (Figure 7A), all putative
N-terminally extended QL9 intermediates should be de-
tectable after trypsin treatment of the HPLC fractions.
Indeed, after the cell extract was HPLC fractionated
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activating 2CZ T cells, we detected three major peaks
containing the QL9 peptide (Figure 7B). The first and
highest peak coeluted with synthetic EPK[QL9] peptide
and the third activity peak with the final QL9 peptide. The
identity of the middle peak is presently unknown. The
presence of the final QL9 peptide is consistant with
the low presentation activity of this precursor observed
in direct presentation assay (Figure 6B). Most impor-
tantly, the predicted ERAAP product EPK[QL9] was
abundant in the cells.
To determine whether any of these peptides were as-
sociated with the Ld MHC, we immunoprecipitated the
endogenous monkey MHC or Ld MHC and analyzed their
peptide content after HPLC fractionation. The material
immunoprecipitated by the Ld monoclonal antibody
(28.14.8S), specific for its a3 domain, from cells express-
ing the antigenic precursor, Ld, and ICP47 contained two
distinct antigenic peaks that coeluted with the EPK[QL9]
and QL9 peptides, respectively (Figure 7C). Trypsin
treatment of the HPLC fractions enhanced 2CZ re-
sponse to the EPK[QL9] peptide, further confirming
that this material in the Ld immunoprecipitate contained
additional N-terminal residues. In contrast, antigenic ac-
tivity was barely detected in the material immunoprecip-
itated from the same cells with the HLA monoclonal
antibody W6/32, which binds to the monkey MHC I
molecules (Figure 7D). Likewise, the material immuno-
precipitated with the same Ld antibody 28.14.8S from
cells expressing the antigenic precursor and ICP47 but
no Ld MHC did not contain detectable antigenic activity.
Similar results were obtained when we analyzed cells in
which peptides were first stripped from the cell surface
before extraction, indicating that the antigenic material
was largely intracellular (Figure S2). We conclude that
the EPK[QL9] is the major product generated after pro-
teolysis of the ES-X3-EPK[QL9] precursor in the ER
and that it is specifically bound to the Ld MHC molecule.
Discussion
The mechanism of ERAAP function and whether MHC I
play any role in generating the final antigenic peptides
are controversial issues. Rammensee and colleagues
first showed that the presence of appropriate MHC mol-
ecules was essential for detecting the final antigenic
peptides in cell extracts (Falk et al., 1990). They sug-
gested that MHC I molecules influenced then-unknown
proteases or that MHC I could even serve as templates
for directing protease activity. However, an alternative
hypothesis suggested that the requirement for the
MHC to detect antigenic peptides was instead due to
their protective role toward independently generated
peptides (Elliott et al., 1990). It was argued that antigenic
peptides were extremely labile, and therefore impossi-
ble to detect unless the MHC I molecules bound and
protected them from certain degradation. Resolving
these opposing ‘‘template’’ versus ‘‘protection’’ models
has remained a challenge.
The analysis of proteolytic events in the MHC I anti-
gen-processing pathway is fraught with technical diffi-
culties. First and foremost is the problem that antigenic
peptides are generated in vanishing amounts in the
APCs. This is of course not an issue when the finalpMHC I is detected on the cell surface by CD8+ T cells
because they have evolved to recognize rare pMHC I
(Purbhoo et al., 2004). Second, the proteolytic interme-
diates, before they are converted to their final form,
are also rare and even harder to detect by conventional
assays (Paz et al., 1999; Kunisawa and Shastri, 2003).
Third, the pMHC I are generated at a very rapid rate in
the APCs or microsomes in vitro, making it difficult to
capture intermediates (Brouwenstijn et al., 2001; Fruci
et al., 2001). Finally, until recently, the molecular mecha-
nism of antigen processing in the ER, the site where
MHC I are loaded with peptides, was unknown and
therefore difficult to manipulate.
The discovery of the ERAAP aminopeptidase as the
catalyst for converting antigenic precursors into their fi-
nal peptide products presented by the MHC I estab-
lished the importance of ER proteolysis in the MHC I an-
tigen-processing pathway (Serwold et al., 2002; York
et al., 2002). When ERAAP-deficient mice also showed
disruptions in their pMHC I repertoire, they provided fur-
ther confirmation of this view as well as new tools for
studying antigen processing in the ER (Hammer et al.,
2006; Yan et al., 2006). To our knowledge, no mamma-
lian cell line is known to lack ERAAP, and therefore the
availability of cells from mice deficient in ERAAP and/
or TAP are key to the analysis of proteolysis that occurs
exclusively in the ER.
All four ER-targeted, N-terminally extended antigenic
precursors required ERAAP expression for generation
of pMHC I on the cell surface. Furthermore, generation
of pMHC I required the presence of an enzymatically ac-
tive form of ERAAP in the ER compartment itself and
thus provided the model system in which normal ERAAP
function could be studied in intact cells. To track the
proteolytic intermediates, we used ER-targeted anti-
genic precursors with a lysine residue flanking the N ter-
minus of the final peptides presented by the appropriate
MHC molecule (Paz et al., 1999). The presence of this ly-
sine residue allowed us to directly detect all possible
N-terminally extended precursors or intermediates in
HPLC-fractionated cell extracts because the optimally
active final peptides are released by trypsin.
The fate of the X6[QL9] precursor and the generation
of the final QL9 peptide was profoundly influenced by
the presence of ERAAP and Ld in the cells. The
X6[QL9] precursor was readily detected in transfected
cells lacking ERAAP with or without the Ld molecule. In
contrast, when the cells expressed both ERAAP and
Ld, the X6[QL9] precursor was undetectable and only
the final QL9 peptide was detected. This shows the re-
markable efficiency with which ERAAP trimmed the
X6[QL9] precursor to its final QL9 product. Moreover,
when ERAAP was expressed in the absence of Ld, the
amount of X6[QL9] precursor or any of its N-terminally
trimmed products was dramatically reduced. An in vitro
analysis of peptide trimming with recombinant ERAAP
also showed that ERAAP was capable of trimming the
X6[QL9], QL9, or SHL8 peptides beyond the minimal
length required for pMHC I expression. Note that in con-
trast to other in vitro studies that used micromolar
amounts, we used picomolar amounts of peptide sub-
strates, and most importantly we analyzed antigen pro-
cessing in living cells that included the appropriate MHC
molecules (Saric et al., 2002; York et al., 2002; Chang
MHC I-Dependent Peptide Trimming by ERAAP
805et al., 2005; Saveanu et al., 2005). Thus, both in vitro and
in living cells, ERAAP did not stop trimming the 15 amino
acid X6[QL9] precursor when it reached a length of 9
amino acids, but trimmed it to a length no longer de-
tected by the T cells. Our analysis therefore does not
support the ‘‘molecular ruler’’ model for ERAAP function
(Chang et al., 2005).
That antigenic precursors for the SHL8 or the QL9
peptides existed in the ER also demonstrates that these
precursors are not impossible to detect, as proposed by
the ‘‘protection’’ model (Elliott et al., 1990). Rather, the
difficulty in detecting these peptides can now be attrib-
uted to their poor antigenicity in conventional assays, as
well as their rapid degradation by ERAAP in the absence
of the relevant MHC I. Paradoxically, this view suggests
that MHC I molecules do serve an important ‘‘protec-
tion’’ function, but instead it is for the precursors of an-
tigenic peptides by saving them from total degradation
by ERAAP. As a corollary, ERAAP can also be seen as
serving a ‘‘janitorial’’ function of keeping the ER free of
worthless peptides that arrive from the cytoplasm but
have no future in the absence of appropriate MHC I
molecules.
Our results confirmed the key prediction of the tem-
plate model that MHC molecules bind N-terminally ex-
tended intermediates (Falk et al., 1990; Brouwenstijn
et al., 2001; Komlosh et al., 2001). We took advantage
of the inability of ERAAP to trim the penultimate
amino-terminal residue preceding a proline residue. As
expected, the presence of a proline prevented ERAAP
from trimming the precursor, and the presentation of
the QL9-Ld complex was inhibited on the cell surface.
Yet, when Ld MHC was immunoprecipitated with an an-
tibody specific for its a3 domain, it was found in specific
association with the predicted 12mer EPK[QL9] peptide.
Given that most reagents (such as antibodies and T
cells) that detect pMHC I are strongly biased toward rec-
ognizing the final pMHC I, it is perhaps not surprising
that such complexes have hitherto gone undetected.
From this role of the MHC I molecule in binding longer
antigenic precursors, we predict that ERAAP will even-
tually be found to interact, if only transiently, with the
peptide-loading complex in the ER.
Taken together, our findings strongly support the orig-
inal template model in which MHC I molecules them-
selves define the peptides (Falk et al., 1990; Brouwen-
stijn et al., 2001). Such a role for the MHC I molecules
is attractive because it can also resolve the efficiency
conundrum inherent in the antigen-processing pathway:
namely, how can the conserved antigen-processing ma-
chinery independently generate the vast collections of
exact peptides to satisfy the binding preferences of
highly polymorphic MHC I molecules? This is no longer
a challenge because the antigen-processing machinery
is not responsible for producing an enormously wasteful
collection of all conceivable peptides that can be pre-
sented by different MHC I (Rammensee et al., 1997). In
an elegant solution, the MHC I and ERAAP can together
produce only those peptides that are suitable for the
MHC I molecules that exist in that APC.
In conclusion, we show here that ERAAP can trim and
eliminate antigenic precursors in the ER. When appro-
priate MHC I are present, they can bind the N-terminally
extended antigenic intermediates and protect themfrom elimination. Concomitantly, this precursor-bound
MHC I complex could serve as a template for ERAAP
to allow removal of only the extra N-terminal flanking
residues. Thus, rather than being mutually exclusive,
the ‘‘protection’’ and ‘‘template’’ models come together
to generate the final pMHC I repertoire.
Experimental Procedures
Cell Lines and T Cell Activation Assay
b-galactosidase (lacZ)-inducible T cell hybridomas B3Z (SHL8-Kb),
11p9Z (WI9-Db), 30NXZ (SVL9-Db), 2CZ (QL9-Ld), and L-cells ex-
pressing Kb, Db, or Ld have been described (Sanderson and Shastri,
1994; Shastri et al., 1998; Serwold et al., 2001). The generation of tail
or embryonic fibroblast cell lines from mice (wild-type, ERAAP-defi-
cient, and ERAAP-TAP double-deficient) has been described (Ham-
mer et al., 2006). The T cells were incubated with the APCs overnight
and produced lacZ in response to the cognate pMHC I expressed by
the transfected cells or by APCs incubated with exogenous syn-
thetic or extracted peptides. LacZ activity was measured by the con-
version of the substrate chlorophenolred-b-D-galacto-pyrannoside
as absorbance at 595 nm (Sanderson and Shastri, 1994).
DNA Constructs and Transfection
The ES-[SHL8], ES-X5[SHL8], ES-X9[SHL8], ES-X7[WI9], ES-
X2[SVL9], ES-X6[QL9], and ES-X3-EPK[QL9] DNA constructs all
encode the ER targeting signal sequence followed by N-terminally
extended (X) antigenic peptides and have been described or were
constructed similarly (Serwold et al., 2001; Hammer et al., 2006).
The human ERAAP cDNA was isolated by PCR from HeLa cell
mRNA and was subcloned into pcDNA I vector. The ERAAPDES is
a mouse ERAAP mutant lacking amino acids 2–20, wherein the first
Met residue is followed by the 21 Gln residue. ERAAPDES insert was
amplified by PCR. The E320A is a single amino acid substitute of hu-
man ERAAP made by site-directed mutagenesis (Glu320 to Ala320).
For transient transfection, the DNA constructs were introduced
into host cells by FuGENE6 (Roche) according to the manufacturer’s
instruction and assayed after 2 days.
Immunohistochemistry and Immunoblots
Expression of ERAAP and its mutants in transfected COS cells was
analyzed as described earlier (Serwold et al., 2002)
Peptides, Peptide Extracts, and HPLC Analysis
All synthetic peptides were prepared by D. King (University of Cali-
fornia at Berkeley) by solid phase synthesis and their purity con-
firmed by mass spectrometry. The preparation of peptide extracts
and their analysis after HPLC fractionation has been described
(Paz et al., 1999). For immunoprecipitation, the 1% NP40 lysates of
COS cells transfected with indicated DNA constructs were coincu-
bated with the Ld monoclonal antibody (28.14.8S) or the pan HLA
monoclonal antibody (W6/32) followed by binding to protein A
Sepharose 4B (Zymed). After washing, the peptides were eluted
by 10% formic acid, fractionated by HPLC, and assayed as de-
scribed above with or without trypsin treatment.
In Vitro Peptide Trimming by Recombinant ERAAP
Recombinant mouse ERAAP (rERAAP) was prepared by Bac-to-Bac
Baculovirus Expression System (Invitrogen) according to the manu-
facturer’s instruction. Recombinant ERAAP was purified by first am-
monium sulfate precipitation followed by ion-exchange HPLC and
was tested for hydrolysis of the chromogenic substrate Leucine p-
nitroanilide (LPNA) in the presence or absence of the inhibitor leuci-
nethiol (Sigma) as described (Serwold et al., 2002). The purity of the
rERAAP was further confirmed by silver staining and immunoblot-
ting with the ERAAP polyclonal antibody (data not shown). For
in vitro peptide trimming assay, synthetic peptides (30 pM) were
incubated with 1.7 mg of rERAAP in 50 ml of 50 mM Tris (pH 7.6) for
90 min or 60 min at 37C in Figures 5B and 5C, respectively. Reaction
was stopped by adding acetic acid and samples were dried by vac-
uum centrifugation. To detect the N-terminally extended peptides,
the samples were treated with 50 mg/ml trypsin, and lac Z response
of appropriate T cells was measured as above. In some experiments,
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was incubated with peptides for 3 hr at 37C before the trimming
assay.
Supplemental Data
Two Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/5/795/DC1/.
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